论文部分内容阅读
[目的]观察ErbB-2与Ebp1蛋白在宫颈癌组织中的表达,并探讨其与宫颈癌临床病理特征的关系及意义.[方法]应用免疫组织化学方法分别检测30例宫颈癌组织及其癌旁组织中ErbB-2与Ebp1蛋白的表达水平.[结果]宫颈癌组织中ErbB-2与Ebp1蛋白的表达水平明显高于癌旁组织(P<0.05),宫颈癌组织中ErbB-2与Ebp1蛋白表达与患者年龄、肿瘤分化程度、家族史无关,ErbB-2与Ebp1蛋白高表达与肿瘤的TNM分期以及淋巴结转移呈正相关(P<0.05).[结论]ErbB-2联合Ebp1蛋白检测有助于宫颈癌转移及预后的判断,Ebp1有望成为宫颈癌基因治疗的生物学靶点.
[Objective] To observe the expression of ErbB-2 and Ebp1 protein in cervical cancer and to explore the relationship between ErbB-2 and Ebp1 protein in clinicopathological features of cervical cancer. [Methods] Immunohistochemistry was used to detect the expression of ErbB- The expression of ErbB-2 and Ebp1 in paracancerous tissue was detected by immunohistochemistry. [Results] The expression levels of ErbB-2 and Ebp1 in cervical cancer tissues were significantly higher than those in paracancerous tissues (P <0.05) The expression of ErbB-2 and Ebp1 protein was positively correlated with TNM stages and lymph node metastasis (P <0.05). [Conclusion] The detection of ErbB-2 and Ebp1 protein is helpful In the judgment of cervical cancer metastasis and prognosis, Ebp1 is expected to become a biological target of cervical cancer gene therapy.